SSI Diagnostica Group is acquiring Gulf Coast Scientific (GCS) located in Florida, USA to further strengthen its gastrointestinal disease testing portfolio.
SSI Diagnostica Group focuses on infectious disease in-vitro diagnostic solutions and antisera and other reagent development for gastric, respiratory and bloodborne diseases. Headquartered in Denmark, the company sells its products in 100 countries worldwide, with direct sales in the Nordics and the USA. It has US locations in California and Virginia with strong R&D capabilities, product development, and state-of-the-art manufacturing from which it serves leading US reference laboratories and hospital labs. GCS specializes in the development of Urea Breath Testing for Helicobacter Pylori (H. Pylori) – a gastric bacteria infecting more than 60 million people annually in the USA alone. The bacteria causes chronic gastritis, gastric cancer, and other cardiovascular and metabolic conditions – diseases critical to detect and treat early at onset to help people live healthier lives.
Acquiring Gulf Coast Scientific complements the company’s gastric portfolio – allowing SSI Diagnostica Group to support its reference and hospital lab customers in the USA and beyond with a broader range of highly specialized products. Jointly, the group will have a total revenue of 850 mDKK (~125 mUSD). The company will consist of nearly 600 talented employees across sites in Denmark, the US and China.
Combining the portfolio of Urea Breath Testing and Rapid Solutions for H. Pylori whilst also offering a strong range of testing for other gastric diseases, e.g. C. Difficile, Lactoferrin and other Foodborne Diseases, makes SSI Diagnostica Group able to offer critical diagnostic solutions for patients with similar symptoms – but with unique urgent treatment needs.
